Table 2.
Characteristics of candidate rotavirus vaccines in development.
| Product | Producer/Developer | Characteristics | Composition | Current stage of development |
|---|---|---|---|---|
| RV3-BB | PT BioFarma, Bandung, Indonesia | Based on human neonatal live-attenuated strain; neonatal (“birth dose”) and infant schedules being evaluated | G3P[6] | Phase 2/3; Phase 2b completed |
| VP8 subunit protein vaccine | PATH Rotavirus Vaccine Program, USA | Subunit vaccine based on recombinant proteins; Parenteral administration being evaluated | Trivalent truncated VP8: P[4],P[6], P[8] | Phase 3 |
| Tetravalent UK-BRV | Shanta Biotechnics | Based on live-attenuated bovine-human reassortant strain | G1–4 | Phase 3, development abandoned |
| Pentavalent UK-BRV | Instituto Butantan, Brazil | Based on live-attenuated bovine-human reassortant strain | G1–4, G9 | Phase 1 |
| Hexavalent UK-BRV | Wuhan Institute of Biological Products, China | Based on live-attenuated bovine-human reassortant strain | G1–4, G8, G9 | Phase 2/3 |
| Inactivated G1P[8] vaccine | CDC, USA | Heat inactivated human strain; Parenteral administration being evaluated | G1P[8] | Preclinical; Animal studies |
| VP6-norovirus VLP | University of Tampere | Subunit vaccine based on virus-like particles; Parenteral administration being evaluated | n/a; VP6 protein | Preclinical: Animal studies |
| expressed VP6 protein | Cincinnati Children’s Hospital Medical Center | Subunit vaccine based on recombinant proteins; Parenteral administration being evaluated | n/a; VP6 protein | Preclinical: Animal studies |
| VLP VP2/6(/7) | Baylor College of Medicine | Subunit vaccine based on virus-like particles; Parenteral administration being evaluated | n/a; VP2/6/7 proteins | Preclinical: Animal studies |